Impact of Human Neutralizing Antibodies on Antitumor Efficacy of an Oncolytic Adenovirus in a Murine Model
Open Access
- 1 November 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (21) , 7199-7206
- https://doi.org/10.1158/1078-0432.ccr-04-0765
Abstract
Purpose: Although NY-ESO-1 was isolated from an esophageal carcinoma patient, its expression in this type of cancer and its immunogenicity in esophageal cancer patients have not yet been fully elucidated. We report here the frequency of NY-ESO-1 mRNA and protein expression in esophageal cancer and the presence of NY-ESO-1-specific immune response in patients.Keywords
This publication has 33 references indexed in Scilit:
- Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patientsCancer Gene Therapy, 2003
- Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2003
- Intravascular adenoviral agents in cancer patients: Lessons from clinical trialsCancer Gene Therapy, 2002
- Impact of Preimmunization on Adenoviral Vector Expression and Toxicity in a Subcutaneous Mouse Cancer ModelMolecular Therapy, 2002
- Systemic Interleukin-6 Responses Following Administration of Adenovirus Gene Transfer Vectors to Humans by Different RoutesMolecular Therapy, 2002
- Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activityGene Therapy, 2001
- Rapid Assessment of Adenovirus Serum Neutralizing Antibody Titer Based on Quantitative, Morphometric Evaluation of Capsid Binding and Intracellular Trafficking: Population Analysis of Adenovirus Capsid Association with Cells Is Predictive of Adenovirus InfectivityJournal of Virology, 2001
- Pre-Existent Adenovirus Antibody Inhibits Systemic Toxicity and Antitumor Activity of CN706 in the Nude Mouse LNCaP Xenograft Model: Implications and Proposals for Human TherapyHuman Gene Therapy, 2000
- Innate Immune Mechanisms Dominate Elimination of Adenoviral Vectors FollowingIn VivoAdministrationHuman Gene Therapy, 1997
- ‘Nude’, a new hairless gene with pleiotropic effects in the mouseGenetics Research, 1966